摘要
目的探讨作为胰高血糖素样肽(glucagon-like peptide-1,GLP-1)受体激动剂的抗2型糖尿病药物利西那肽(lixisenatid,商品名Lyxumia)的临床研究进展,为其进一步研究提供一定的参考。方法基于对已有文献、报道的分析与整理,阐述利西那肽的作用机制及临床研究进展。结果利西那肽作为一种新型的抗2型糖尿病药物,在增加胰岛素分泌、控制胰高血糖素分泌,以及空腹、餐后血糖水平等方面具有优异的性能。此外,相比于其他GLP-1受体激动剂,利西那肽还可以降低心血管病的发病风险。结论临床研究实验表明,使用利西那肽患者的糖化血红蛋白含量显著降低,空腹、餐后血糖浓度得以控制在合理范围内。同时,利西那肽不引起患者体质量显著增加,产生突发性低血糖事件的风险明显降低,安全且高效,具有极好的发展前景。
Objective To study the progress of clinical research of lixisenatide（ Lyxumia） as one of the glucagon-like peptide（ GLP）-1 receptor agonists which is used to treat T2 DM,thus provides references and helps to the further research. Methods Based on the analyzing and tiding of published literatures,the mechanism of action and clinical research progress of lixisenatide were described. Results Lixisenatide as a newmember of glucagon-like peptide（ GLP）-1 receptor agonist to defend T2 DM,it showed excellent properties in increasing insulin secretion,inhibiting of glucagon secretion and controlling the level of fasting and postprandial plasma glucose. In addition,comparing to other glucagon-like peptide（ GLP）-1 receptor agonists,lixisenatide could also reduce the risk of cardiovascular diseases. Conclusions The clinical program proves that lixisenatide has the good safety and tolerability,it can significantly reduce the value of Hb A1 c and substantialy control fasting and postprandial plasma glucose within a normal level. Meanwhile,it would not lead to an obviously increase in body weight and reduce the risk of hypoglycemia,therefore,it has a bright future in defending T2 DM.
作者
韩佳婧
刘冰弥
陈烨
刘宇
HAN Jiajing;LIU Bingmi;CHEN Ye;LIU Yu(School of Pharmacy, Liaoning University, Shenyang 110036, China)
出处
《沈阳药科大学学报》
CAS
CSCD
北大核心
2018年第5期424-430,共7页
Journal of Shenyang Pharmaceutical University
基金
国家自然科学基金青年基金资助项目(81503024)
